Propanc Biopharma (PPCB) Change in Accured Expenses (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Change in Accured Expenses of -$365645.0 for Q4 2025, down 1174.38% year-over-year from $34033.0 in Q4 2024, and down 2715.11% quarter-over-quarter from $13982.0 in Q3 2025.
Propanc Biopharma (PPCB) Change in Accured Expenses (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Change in Accured Expenses for 15 consecutive years, with -$365645.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 1174.38% year-over-year to -$365645.0; the TTM figure through Dec 2025 stood at -$145858.0 (down 9092.48% YoY), while the FY2025 annual figure was $255155.0, up 418.65% from the prior year.
- Change in Accured Expenses retreated to -$365645.0 in Q4 2025 per PPCB's latest filing, from $13982.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $292873.0 in Q1 2025 and bottomed at -$365645.0 in Q4 2025.
- Historically, Change in Accured Expenses has averaged $8230.7 across 5 years, with a median of $13427.0 in 2022.
- On a YoY basis, Change in Accured Expenses climbed as much as 1066.0% in 2022 and fell as far as 3079.51% in 2022.
- Propanc Biopharma's Change in Accured Expenses stood at $1544.0 in 2021, then surged by 1066.0% to $18003.0 in 2022, then soared by 351.1% to $81212.0 in 2023, then sank by 58.09% to $34033.0 in 2024, then slumped by 1174.38% to -$365645.0 in 2025.
- Business Quant data shows PPCB's Change in Accured Expenses at -$365645.0 in Q4 2025, $13982.0 in Q3 2025, and -$87068.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 9,816.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -365,645.00 |
| Dec 31, 2025 | -365,645.00 |
| Sep 30, 2025 | 13,982.00 |
| Sep 30, 2025 | 13,982.00 |
| Jun 30, 2025 | -87,068.00 |
| Jun 30, 2025 | -87,068.00 |
| Mar 31, 2025 | 292,873.00 |
| Mar 31, 2025 | 292,873.00 |
| Dec 31, 2024 | 34,033.00 |
| Dec 31, 2024 | 34,033.00 |
| Sep 30, 2024 | 15,317.00 |
| Sep 30, 2024 | 15,317.00 |
| Jun 30, 2024 | 13,424.00 |
| Jun 30, 2024 | 13,424.00 |
| Mar 31, 2024 | -61,152.00 |
| Mar 31, 2024 | -61,152.00 |
| Dec 31, 2023 | 81,212.00 |
| Dec 31, 2023 | 81,212.00 |
| Sep 30, 2023 | 15,712.00 |
| Sep 30, 2023 | 15,712.00 |